Online citations, reference lists, and bibliographies.

Survival Effect Of Maximal Cytoreductive Surgery For Advanced Ovarian Carcinoma During The Platinum Era: A Meta-analysis.

R. Bristow, R. Tomacruz, D. Armstrong, E. Trimble, F. Montz
Published 2002 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
PURPOSE To evaluate the relative effect of percent maximal cytoreductive surgery and other prognostic variables on survival among cohorts of patients with advanced-stage ovarian carcinoma treated with platinum-based chemotherapy. MATERIALS AND METHODS Eighty-one cohorts of patients with stage III or IV ovarian carcinoma (6,885 patients) were identified from articles in MEDLINE (1989 through 1998). Linear regression models, with weighted correlation calculations, were used to assess the effects on log median survival time of the proportion of each cohort undergoing maximal cytoreduction, dose-intensity of the platinum compound administered, proportion of patients with stage IV disease, median age, and year of publication. RESULTS There was a statistically significant positive correlation between percent maximal cytoreduction and log median survival time, and this correlation remained significant after controlling for all other variables (P <.001). Each 10% increase in maximal cytoreduction was associated with a 5.5% increase in median survival time. When actuarial survival was estimated, cohorts with < or = 25% maximal cytoreduction had a mean weighted median survival time of 22.7 months, whereas cohorts with more than 75% maximal cytoreduction had a mean weighted median survival time of 33.9 months--an increase of 50%. The relationship between platinum dose-intensity and log median survival time was not statistically significant. CONCLUSION During the platinum era, maximal cytoreduction was one of the most powerful determinants of cohort survival among patients with stage III or IV ovarian carcinoma. Consistent referral of patients with apparent advanced ovarian cancer to expert centers for primary surgery may be the best means currently available for improving overall survival.
This paper references
10.1200/jco.1994.12.10.2066
Long-term follow-up of the first randomized study of cisplatin versus carboplatin for advanced epithelial ovarian cancer.
A. Taylor (1994)
10.1006/gyno.1997.4690
Randomized Study Comparing Carboplatin/Cyclophosphamide and Cisplatin/Cyclophosphamide as First-Line Treatment in Patients with Stage III/IV Epithelial Ovarian Cancer and Small Volume Disease
H. Meerpohl (1997)
A meta-analysis of residual disease and survival in stage III and IV carcinoma of the ovary.
Allen Dg (1995)
10.1200/JCO.1992.10.5.718
Cisplatin-cyclophosphamide versus carboplatin-cyclophosphamide in advanced ovarian cancer: a randomized phase III study of the National Cancer Institute of Canada Clinical Trials Group.
K. Swenerton (1992)
10.1016/0090-8258(92)90067-S
The effect of prolonged cisplatin-based chemotherapy on progression-free survival in patients with optimal epithelial ovarian cancer: "Maintenance" therapy reconsidered
D. Gershenson (1992)
10.1200/JCO.1997.15.5.1938
Weekly cisplatin given for 2 months versus cisplatin plus cyclophosphamide given for 5 months after cytoreductive surgery for advanced ovarian cancer.
G. Bolis (1997)
10.1159/000238673
A randomized study of high-dose versus low-dose cis-platinum combined with cyclophosphamide in the treatment of advanced ovarian cancer. Hong Kong Ovarian Carcinoma Study Group.
H. Ngan (1989)
10.1200/JCO.1991.9.10.1793
Cisplatin, carboplatin, and cyclophosphamide combination chemotherapy in advanced-stage ovarian carcinoma: an Eastern Cooperative Oncology Group pilot study.
J. Grem (1991)
10.1016/0002-9378(92)91658-W
Meta-analysis of surgery in advanced ovarian carcinoma: is maximum cytoreductive surgery an independent determinant of prognosis?
R. Hunter (1992)
10.1093/annonc/2.suppl_2.131
Management of follicular lymphoma
A. Rohatiner (1994)
Extensive cytoreductive surgery in advanced ovarian carcinoma.
G. Michel (1997)
10.1006/gyno.1996.0334
"MECCA": a developmental, dose-intensive, non-cross-resistant platinum-based chemotherapy for advanced ovarian cancer.
P. Hoskins (1996)
10.1016/0020-7292(91)90100-J
Tumor reduction surgery and long-term survival in advanced ovarian cancer: A DACOVA study
K. Bertelsen (1990)
10.1006/GYNO.1997.4845
Ifosfamide plus cisplatin as primary chemotherapy of advanced ovarian cancer.
C. Vallejos (1997)
10.1200/JCO.1991.9.4.658
Carboplatin, doxorubicin, and cyclophosphamide versus cisplatin, doxorubicin, and cyclophosphamide: a randomized trial in stage III-IV epithelial ovarian carcinoma.
P. Conte (1991)
10.1034/j.1600-0412.1998.770714.x
Prognosis of 2,800 patients with epithelial ovarian cancer diagnosed during 1975‐94 and treated at the Norwegian Radium Hospital
T. Bjørge (1998)
10.1001/JAMA.280.20.1747
Impact of hospital volume on operative mortality for major cancer surgery.
C. Begg (1998)
10.1200/jco.1989.7.4.457
Randomized trial of cyclophosphamide plus cisplatin with or without doxorubicin in ovarian carcinoma: a Gynecologic Oncology Group Study.
G. Omura (1989)
10.1038/bjc.1994.440
The influence of the operating surgeon's specialisation on patient survival in ovarian carcinoma.
S. Kehoe (1994)
10.1111/j.1471-0528.1997.tb11032.x
What changes in the organisation of cancer services will improve the outcome for women with ovarian cancer?
C. Woodman (1997)
10.3109/07357909309020253
Chemotherapy consisting of cisplatin, epirubicin, and cyclophosphamide in advanced ovarian carcinoma. The Gynecologic Oncology Group of the Comprehensive Cancer Center, Limburg, The Netherlands.
J. Stoot (1993)
10.1016/0002-9378(92)91554-N
Advanced epithelial ovarian carcinoma: long-term survival experience at the community hospital.
R. F. Unzelman (1992)
10.1038/bjc.1993.502
A randomised study of carboplatin vs sequential ifosfamide/carboplatin for patients with FIGO stage III epithelial ovarian carcinoma. The London Gynaecologic Oncology Group.
T. Perren (1993)
10.1016/0002-9378(79)90824-X
Rewiew of ovarian cancer at the University of Texas Systems Cancer Center, M.D. Anderson Hospital and Tumor Institute.
J. P. Smith (1979)
10.1016/0002-9378(92)91345-B
The cavitational ultrasonic surgical aspirator for cytoreduction in advanced ovarian cancer
P. Rose (1992)
10.1006/GYNO.2000.5923
High-dose platinum versus standard dose in advanced ovarian carcinoma: a randomized trial from the Gynecologic Cooperative Group of the French Comprehensive Cancer Centers (FNCLCC).
F. Joly (2000)
10.1016/S0002-9378(15)33580-8
The changing prognosis and treatment in cancer of the ovary
E. W. Munnell (1968)
10.3109/07853899509031943
Primary surgery in ovarian cancer: current opinions.
T. Hoegberg (1995)
10.1006/gyno.1994.1142
Extensive primary cytoreductive surgery for advanced epithelial ovarian cancer.
F. Guidozzi (1994)
10.3322/canjclin.51.1.15
Cancer Statistics, 2001
R. Greenlee (2001)
Randomized comparison of cyclophosphamide, doxorubicin and cisplatin (CAP) versus cyclophosphamide and doxorubicin (CA) for the treatment of advanced ovarian cancer (ADOVCA). A EORTC Gynecological Cancer Cooperative Group Study.
C. F. de Oliveira (1990)
10.1093/jnci/81.19.1464
Randomized trial in advanced ovarian cancer comparing cisplatin and carboplatin.
C. Mangioni (1989)
10.1046/j.1525-1438.1992.02050236.x
Carboplatin with cyclophosphamide in patients with advanced ovarian cancer: an efficacy and quality-adjusted survival analysis
P. Willemse (1992)
10.1006/GYNO.1998.4955
Complete cytoreductive surgery is feasible and maximizes survival in patients with advanced epithelial ovarian cancer: a prospective study.
S. Eisenkop (1998)
10.1038/bjc.1994.307
Management of ovarian cancer: referral to a multidisciplinary team matters.
E. Junor (1994)
10.1002/jso.2930480108
Five-year survival for cisplatin-based chemotherapy versus single-agent melphalan in patients with advanced ovarian cancer and optimal debulking surgery.
M. River (1991)
Five year follow-up and dose delivery analysis of cisplatin, iproplatin or carboplatin in combination with cyclophosphamide in advanced ovarian carcinoma.
H. Gurney (1990)
10.1016/0959-8049(95)00537-4
Carboplatin alone compared with its combination with epirubicin and cyclophosphamide in untreated advanced epithelial ovarian cancer: a Hellenic co-operative oncology group study.
D. Skarlos (1996)
10.3109/02841868909111182
A comparison of the toxicity and efficacy of cisplatin and carboplatin in advanced ovarian cancer. The Swons Gynaecological Cancer Group.
M. Adams (1989)
10.1093/oxfordjournals.annonc.a057796
Original article: Five year follow-up and dose delivery analysis of cisplatin, iproplatin or carboplatin in combination with cyclophosphamide in advanced ovarian carcinoma
H. Gurney (1990)
10.1002/jso.2930460315
Chemotherapy with high dose ifosfamide/mesna plus cisplatin for the treatment of ovarian cancer: a study of the Grupo de Estudio y Tratamiento Latino-Americano del Cancer.
C. Araujo (1991)
10.3109/07853899509031944
Prospective randomized trials on cytoreduction in ovarian cancer.
P. van Geene (1995)
10.1046/j.1525-1438.1992.02060301.x
Novel, dose intensive, single-agent cisplatin in the first-line management of advanced stage ovarian cancer
M. Palmer (1992)
10.1046/j.1525-1438.1996.06010044.x
An evaluation of the policy of routine treatment of advanced epithelial ovarian carcinoma by debulking surgery and combined platinum‐cyclophosphamide chemotherapy in Singapore
S. Tay (1996)
10.1038/sj.bjc.6690376
An audit of primary surgical treatment for women with ovarian cancer referred to a cancer centre
P. Sengupta (1999)
10.1006/gyno.1994.1082
Long-term survival in advanced ovarian cancer after cytoreduction and chemotherapy treatment.
J. D. del Campo (1994)
10.1200/JCO.1990.8.3.502
High-dose cisplatin combination chemotherapy in the treatment of advanced epithelial ovarian carcinoma.
J. D. Hainsworth (1990)
10.1200/jco.1995.13.7.1589
Assessment of dose-intensive therapy in suboptimally debulked ovarian cancer: a Gynecologic Oncology Group study.
W. Mcguire (1995)
10.1200/JCO.1996.14.2.351
High-dose versus low-dose cisplatin in combination with cyclophosphamide and epidoxorubicin in suboptimal ovarian cancer: a randomized study of the Gruppo Oncologico Nord-Ovest.
P. Conte (1996)
10.1046/j.1525-1438.1996.06050410.x
Combined high-dose platinum and etoposide in previously untreated ovarian cancer patients with residual disease
G. Strauss (1996)
10.1016/0090-8258(92)90110-5
Ovarian cancer staging: does it require a gynecologic oncologist?
A. Mayer (1992)
10.1016/S0002-9378(96)70331-9
Ultraradical debulking of epithelial ovarian cancer with the ultrasonic surgical aspirator: a prospective randomized trial.
P. V. van Dam (1996)
10.1046/J.1525-1438.1998.97110.X
Continuous infusion of ifosfamide and cisplatin as first‐line therapy of patients with suboptimally debulked stage III–IV epithelial ovarian cancer
Malik (1998)
10.1016/0090-8258(89)90636-7
Treatment of advanced epithelial ovarian cancer with cisplatin and cyclophosphamide.
D. Gershenson (1989)
10.1016/0090-8258(85)90141-6
Assessment of morbidity and mortality in primary cytoreductive surgery for advanced ovarian carcinoma.
S. S. Chen (1985)
10.1006/gyno.1995.1273
Meta-analysis comparing cisplatin total dose intensity and survival.
Y. Ben-David (1995)
10.1378/CHEST.114.3.675
Specialists achieve better outcomes than generalists for lung cancer surgery.
G. Silvestri (1998)
10.1002/1098-2388(200007/08)19:1<42::AID-SSU7>3.0.CO;2-M
Cytoreductive surgery for advanced stages of ovarian cancer.
J. Dauplat (2000)
10.1006/gyno.1995.1241
Combined cisplatin and carboplatin chemotherapy for treatment of advanced epithelial ovarian cancer.
D. Gershenson (1995)
10.1006/gyno.1993.1091
Treatment of advanced ovarian carcinoma in the elderly.
D. Marchetti (1993)
10.1016/0090-8258(92)90107-T
The impact of subspecialty training on the management of advanced ovarian cancer.
S. Eisenkop (1992)
10.1097/00000658-199909000-00013
Hospital volume can serve as a surrogate for surgeon volume for achieving excellent outcomes in colorectal resection.
J. Harmon (1999)
10.1002/(SICI)1097-0142(19981101)83:9<1980::AID-CNCR14>3.0.CO;2-O
Dose intensive combination platinum and cyclophosphamide in the treatment of patients with advanced untreated epithelial ovarian cancer
J. Shapiro (1998)
10.1006/GYNO.2001.6460
A population-based study of patterns of care for ovarian cancer: who is seen by a gynecologic oncologist and who is not?
M. Carney (2002)
10.1136/ijgc-00009577-199609001-00007
The role of intervention debulking surgery in advanced epithelial ovarian cancer: an EORTC Gynecological Cancer Cooperative Group study
M. V. D. VAN DER BURG (1996)
10.1200/JCO.2000.18.11.2327
Hospital and physician volume or specialization and outcomes in cancer treatment: importance in quality of cancer care.
B. Hillner (2000)
Epithelial Ovarian Cancer: Impact of Surgery and Chemotherapy on Survival During 1977–1990
P. Venesmaa (1994)
10.1200/jco.1988.6.6.983
The impact of aggressive debulking surgery and cisplatin-based chemotherapy on progression-free survival in stage III and IV ovarian carcinoma.
M. Piver (1988)
10.1001/jama.1993.03500090055032
Staging procedures, clinical management, and survival outcome for ovarian carcinoma.
R. Hand (1993)
10.1016/0277-5379(89)90208-3
A meta-analysis of prognostic factors in advanced ovarian cancer with median survival and overall survival (measured with the log (relative risk)) as main objectives.
E. Voest (1989)
10.1056/NEJM199612263352603
Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer.
D. Alberts (1996)
National survey of ovarian carcinoma. I. A patient care evaluation study of the American College of Surgeons.
H. Averette (1993)
10.1006/gyno.1995.1027
The prognostic significance of residual disease, FIGO substage, tumor histology, and grade in patients with FIGO stage III ovarian cancer.
A. Makar (1995)
10.1016/0090-8258(86)90001-6
The potential for optimal (⩽ 2 cm) cytoreductive surgery in advanced ovarian carcinoma at a tertiary medical center: A prospective study
M. Piver (1986)
10.1016/0090-8258(91)90222-Q
Improved prognosis of ovarian cancer in The Netherlands during the period 1975–1985: A registry-based study
H. R. Balvert-locht (1991)
10.1002/(SICI)1097-0142(19960215)77:4<733::AID-CNCR20>3.0.CO;2-0
Randomized trial of initial therapy with melphalan versus cisplatin‐based combination chemotherapy in patients with advanced ovarian carcinoma: Initial and long term results—Eastern Cooperative Oncology Group study E2878
S. Wadler (1996)
Primary Cytoreductive Surgery for Epithelial Ovarian Cancer
N. Hacker (1983)
10.1093/jnci/85.21.1732
Importance of multiagent chemotherapy regimens in ovarian carcinoma: dose intensity analysis.
L. Levin (1993)
10.1046/j.1525-1438.7.s1.5.x
Combination paclitaxel (Taxol®)-cisplatin vs cyclophosphamide-cisplatin as primary therapy in patients with suboptimally debulked advanced ovarian cancer
W. Hoskins (1997)
10.1002/CNCR.2820710221
Patterns of care in carcinoma of the ovary
L. McGowan (1993)
10.1002/CNCR.2820710220
Analysis of patient age as an independent prognostic factor for survival in a phase III study of cisplatin–cyclophosphamide versus carboplatin–cyclophosphamide in stages III (suboptimal) and IV ovarian cancer: A southwest oncology group study
D. Alberts (1993)
10.1016/0020-7292(87)90198-6
Cytoreductive surgery in ovarian carcinoma: feasibility and morbidity.
A. Heintz (1986)
10.1016/0305-7372(91)90023-S
Randomized comparison of hexamethylmelamine, adriamycin, cyclophosphamide (HAC) vs. cisplatin, adriamycin, cyclophosphamide (PAC) in advanced ovarian cancer: long-term results.
C. Sessa (1991)
10.1016/0959-8049(95)00274-M
A phase II study of carboplatin and hexamethylmelamine as induction chemotherapy in advanced epithelial ovarian carcinoma.
G. Kristensen (1995)
10.1038/bjc.1992.55
A randomised study comparing standard dose carboplatin with chlorambucil and carboplatin in advanced ovarian cancer.
E. Rankin (1992)
10.1016/0090-8258(92)90100-W
The influence of cytoreductive surgery on recurrence-free interval and survival in small-volume stage III epithelial ovarian cancer: a Gynecologic Oncology Group study.
W. Hoskins (1992)
10.1006/GYNO.1997.4913
Combined carboplatin plus ifosfamide and cisplatin in patients with advanced ovarian carcinoma. A phase I-II study. GOCS (Gynecological Oncology Cooperative Study).
V. Lorusso (1998)
The potential of primary cytoreductive surgery in patients with FIGO stages III and IV ovarian carcinoma.
P. Fioretti (1990)
10.1016/0020-7292(91)90782-Z
A randomized trial of cyclophosphamide, doxorubicin, and cisplatin with or without bacillus Calmette-Guerin in patients with suboptimal stage III and IV ovarian cancer: A Gynecologic Oncology Group Study☆
W. Creasman (1990)
10.1056/NEJM199601043340101
Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer.
W. Mcguire (1996)
10.1200/JCO.1989.7.2.223
Ten-year follow-up of patients receiving cisplatin, doxorubicin, and cyclophosphamide chemotherapy for advanced epithelial ovarian carcinoma.
G. Sutton (1989)
10.1006/gyno.1993.1081
A prospective randomized comparison of 6 and 12 cycles of cyclophosphamide, adriamycin, and cisplatin in advanced epithelial ovarian cancer: a Danish Ovarian Study Group trial (DACOVA).
K. Bertelsen (1993)
10.1200/JCO.1992.10.4.520
Relationships between carboplatin exposure and tumor response and toxicity in patients with ovarian cancer.
D. Jodrell (1992)
10.1016/0090-8258(83)90055-0
Prognostic factors in malignant epithelial ovarian tumors.
K. Sigurdsson (1983)
Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma.
Griffiths Ct (1975)
10.1093/oxfordjournals.annonc.a057876
Cisplatin and carboplatin in combination for the treatment of stage IV ovarian carcinoma.
J. Hardy (1991)
10.1097/00000421-199710000-00019
Long-term results in patients with advanced epithelial ovarian carcinoma treated with a combination of cisplatin, doxorubicin, and cyclophosphamide.
M. Colozza (1997)
10.1111/j.1471-0528.1999.tb08137.x
Specialist gynaecologists and survival outcome in ovarian cancer: a Scottish national study of 1866 patients
E. Junor (1999)
10.1006/GYNO.2000.5926
A critique of surgical cytoreduction in advanced ovarian cancer.
A. Covens (2000)
10.1006/gyno.1994.1220
A comparison of intravenous versus intraperitoneal chemotherapy for the initial treatment of ovarian cancer.
S. Kirmani (1994)
10.1159/000227155
A cisplatinum-cyclophosphamide regimen in advanced ovarian cancer: reporting 5-year results.
M. Locatelli (1993)
10.1016/0090-8258(92)90305-3
Randomized prospective trial of 5 versus 10 cycles of cyclophosphamide, doxorubicin, and cisplatin in advanced ovarian carcinoma.
T. Hakes (1992)
10.1002/1097-0142(19931215)72:12<3663::AID-CNCR2820721218>3.0.CO;2-S
National survey of ovarian carcinoma part V. The impact of physician's specialty on patients' survival
H. Nguyen (1993)
10.1002/1097-0142(19940715)74:2<656::AID-CNCR2820740218>3.0.CO;2-6
Long term survival by cytoreductive surgery to less than 1 cm, induction weekly cisplatin and monthly cisplatin, doxorubicin, and cyclophosphaide therapy in advanced ovarian adenocarcinoma
T. Baker (1994)



This paper is referenced by
10.1097/IGC.0000000000000598
Surgery for Recurrent Epithelial Ovarian Cancer in the Netherlands: A Population-Based Cohort Study
R. van de Laar (2015)
10.1097/IGC.0000000000001247
Ovarian Cancer Surgery in Australia and New Zealand: A Survey to Determine Changes in Surgical Practice Over 10 Years
Rhonda Farrell (2018)
10.1245/s10434-009-0558-6
Does Neoadjuvant Chemotherapy Increase Optimal Cytoreduction Rate in Advanced Ovarian Cancer? Meta-Analysis of 21 Studies
S. Kang (2009)
Exenteração pélvica posterior modificada para o câncer de ovário: dez anos de experiência em 17 casos operados
S. Costa (2008)
10.1002/jso.21470
Secondary cytoreductive surgery in the management of platinum-sensitive recurrent epithelial ovarian cancer.
Jeong-Yeol Park (2010)
10.1016/j.ygyno.2009.11.033
Achievements and unmet needs in the management of advanced ovarian cancer.
V. Guarneri (2010)
Heterogeneous expression of serine protease inhibitor maspin in ovarian cancer.
D. Bauerschlag (2010)
10.1002/jso.21686
Survival after secondary cytoreduction for recurrent ovarian cancer: which are the prognostic factors?
Ioannis Biliatis (2010)
Establishment and characterization of a novel ovarian serous adenocarcinoma cell line, TU-OS-4, that overexpresses EGFR and HER2
Hiroaki ItamochiMisaki (2012)
10.1002/jcb.24317
Cancerous ovarian stem cells: obscure targets for therapy but relevant to chemoresistance.
N. Ahmed (2013)
10.1016/j.ygyno.2014.07.103
Impact of obesity on surgical and oncologic outcomes in ovarian cancer.
A. Kumar (2014)
10.1586/14737140.2016.1168699
The clinical management of inoperable endometrial carcinoma
Marguerite L Palisoul (2016)
10.1016/J.JGYN.2011.02.009
Impact des curages rétropéritonéaux sur la survie des patientes atteintes d'un cancer de l'ovaire à un stade avancé: le protocole CARACO
Jean-Marc Classe (2011)
10.1038/bjc.2011.219
A seven-gene prognostic model for platinum-treated ovarian carcinomas
R. Sabatier (2011)
10.7314/APJCP.2014.15.15.6087
Impact of prognostic factors on survival rates in patients with ovarian carcinoma.
Sevim Kalsen Arikan (2014)
10.4103/1008-682X.196852
Risk of complications and urinary incontinence following cytoreductive prostatectomy: a multi-institutional study
D. Kim (2018)
Surgical treatment of ovarian cancer Chirurgiczne leczenie raka jajnika
Mariusz Bidziński (2008)
10.1089/jpm.2017.0679
Top 10 Tips Palliative Care Clinicians Should Know When Caring for Patients with Ovarian Cancer.
Brittany A Davidson (2018)
10.18632/oncotarget.12784
Reduced expression of FILIP1L, a novel WNT pathway inhibitor, is associated with poor survival, progression and chemoresistance in ovarian cancer
M. Kwon (2016)
10.3390/cancers12030559
Impact of CT-Determined Sarcopenia and Body Composition on Survival Outcome in Patients with Advanced-Stage High-Grade Serous Ovarian Carcinoma
Se Seung Kim (2020)
10.1080/00015458.2004.11679550
Role of Surgery in Ovarian Cancer: An Update
I. Vergote (2004)
10.3802/jgo.2016.27.e5
Incidence of epithelial ovarian cancer according to histologic subtypes in Korea, 1999 to 2012
S. Kim (2016)
10.2174/1381612825666190722112808
Sarcopenia in ovarian cancer patients, oncologic outcomes revealing the importance of clinical nutrition: review of literature.
S. Cianci (2019)
10.1016/j.ejso.2020.04.029
Prognostic factors of overall survival for patients with FIGO stage IIIc or IVa ovarian cancer treated with neo-adjuvant chemotherapy followed by interval debulking surgery: A multicenter cohort analysis from the FRANCOGYN study group.
Lehoock Vincent (2020)
Sustained-release implants for intraperitoneal cisplatin delivery
Aikaterini Mantzavinou (2018)
10.1111/j.1440-1843.2012.02177.x
Clinical implications of pleural effusions in ovarian cancer.
J. M. Porcel (2012)
10.3109/01443615.2014.899330
CT scan does not predict optimal debulking in stage III–IV epithelial ovarian cancer: A multicentre validation study
M. Mackintosh (2014)
10.1080/23809000.2016.1185369
The management of malignant ascites and impact on quality of life outcomes in women with ovarian cancer
Rudy S. Suidan (2016)
10.1111/j.1471-0528.2012.03297.x
Triaging women with ovarian masses for surgery: observational diagnostic study to compare RCOG guidelines with an International Ovarian Tumour Analysis (IOTA) group protocol
B. van Calster (2012)
10.1016/J.AJOG.2005.06.074
Safety and efficacy of cytoreductive surgery for epithelial ovarian cancer in elderly and high-risk surgical patients.
S. Sharma (2005)
10.1016/S0002-9440(10)63661-9
The function of COX-2 in human ovarian carcinoma.
R. Agarwal (2003)
10.1002/14651858.CD007697.pub2
Ultra-radical (extensive) surgery versus standard surgery for the primary cytoreduction of advanced epithelial ovarian cancer.
C. Ang (2011)
See more
Semantic Scholar Logo Some data provided by SemanticScholar